[Skip to the reading](/#reading) # Peptide Therapy News [Regulatory](/regulatory) [Research](/research) [Archive](/#event-index) [About](/about) Source review through 27 October 2026 · Event dates appear with reports Peptide research and FDA decisions, in plain words. What happened, what it means, and where the evidence stops. ![A commuter reading a folded newspaper on a morning train, with the printed page turned away.](/press-desk-66428b6910dc/cover.webp) Illustration: catching up on the morning train. Regulatory ## The shortage ended. Local gaps could still happen. Event · 21 February 2025 FDA chronology updated · 1 April 2026 FDA said national supplies of semaglutide injections could meet demand. That changed the rules for compounded copies, too. A supply decision and a drug approval are still different things. [Read the full lead](/#lead-report) ## What the end of the shortage changed Event · 21 February 2025 FDA chronology updated · 1 April 2026 ### What happened On 21 February 2025, FDA [declared the national shortage of semaglutide injections over](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize). Manufacturing could meet U.S. demand, the agency said. That didn’t mean every local shelf would stay stocked. Tirzepatide had its own timeline: an initial decision on 2 October 2024, then a new decision on 19 December after another review. The two medicines didn’t leave the shortage list together. ### What it means The shortages had allowed certain compounded copies: medicines prepared by a pharmacy or another authorized facility, rather than an approved finished product. Once national supplies recovered, those shortage-based exceptions ended after temporary grace periods. For semaglutide, the original pharmacy deadline was 22 April 2025, or the court’s ruling if later. FDA confirmed that period had ended after the 24 April ruling. Larger outsourcing facilities had until 22 May. The [regulatory page](/regulatory) puts those dates in order. Neither semaglutide nor tirzepatide has FDA approval in compounded form. FDA has [reported medication errors with compounded semaglutide](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss), including some requiring hospital care. A licensed U.S. clinician can discuss approved treatments and an individual’s needs. ## Research ### Retatrutide results came from two different groups Event · 26 June 2023 ADA announcement · 26 June 2023 #### What happened On 26 June 2023, the American Diabetes Association [announced two retatrutide trials](https://diabetes.org/sites/default/files/2023-10/ada_sci_sessions_2023_news_release_retatrutide_0.pdf). These were phase 2 studies: mid-stage human testing. One studied adults without type 2 diabetes; the other studied adults with it. #### What it means The [obesity trial](https://pubmed.ncbi.nlm.nih.gov/37366315/) found weight loss, alongside stomach side effects and a faster heartbeat. Retatrutide is an unapproved investigational drug. [FDA says it cannot be compounded](https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) under federal law; a trial result doesn’t change that. [Read the retatrutide report](/research) ### Less liver fat in a study of adults with HIV Event · 15 October 2019 NIH announcement · 15 October 2019 #### What happened On 15 October 2019, NIH [reported a year-long tesamorelin trial](https://www.nih.gov/news-events/news-releases/drug-reverses-signs-liver-disease-people-living-hiv) in adults with HIV and fatty liver disease. Liver fat fell more with tesamorelin than with placebo, a comparison treatment without the medicine. #### What it means That finding doesn’t make tesamorelin a general weight-loss treatment. Its [prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75) warns about blood sugar and fluid retention. The [full report](/tesamorelin) explains what was studied and what is approved. [Follow the tesamorelin record](/tesamorelin) ## The dated record Decisions and research announcements, ordered from newest to oldest. - 25 March 2025 [Tesamorelin formulation supplement approved](/tesamorelin#formulation) FDA approval letter - 21 February 2025 [Semaglutide injection shortage declared resolved](/regulatory#shortage-record) FDA shortage chronology - 19 December 2024 [FDA issues a new tirzepatide shortage decision](/regulatory#shortage-record) FDA shortage chronology - 8 March 2024 [Semaglutide gains a heart-risk indication](/semaglutide) FDA approval announcement - 26 June 2023 [Retatrutide phase 2 findings announced](/research) American Diabetes Association - 15 October 2019 [NIH reports tesamorelin liver-fat findings](/tesamorelin#liver-finding) NIH announcement - 10 November 2010 [Original tesamorelin approval](/tesamorelin#original-approval) FDA approval letter The [FDA peptide table](/regulatory#withdrawn-record) is current as of 22 April 2026. It gives no date for each withdrawn request. Peptide Therapy News is a guide for reading the record, not a clinic, pharmacy or seller. © 2026 Peptide Therapy News [References](/references) [About](/about) [Contact](/contact) [Event index](/#event-index)